[Skip to the reading](/research#reading)

[Peptide Therapy News](/)

[Regulatory](/regulatory) [Research](/research)

[Archive](/#event-index) [About](/about)

Source review through 27 October 2026 · Event dates appear with reports

[Home](/) / Research

# Retatrutide had two different trial headlines

Both studies made news on 26 June 2023. One involved adults with type 2 diabetes. The other didn’t. That difference matters when you read the results.

## What the two studies found

Event · 26 June 2023

ADA announcement · 26 June 2023

![A microscopy-style pancreatic islet surrounded by darker exocrine tissue.](/press-desk-66428b6910dc/research.webp)

Illustration: pancreatic tissue and its hormone-producing islet, not a trial specimen.

### What happened

The American Diabetes Association [announced two retatrutide studies](https://diabetes.org/sites/default/files/2023-10/ada_sci_sessions_2023_news_release_retatrutide_0.pdf) on 26 June 2023. Both were phase 2 trials, a [mid-stage part of human testing](https://www.fda.gov/patients/drug-development-process/step-3-clinical-research) that examines whether a treatment works and what side effects it causes. Encouraging results still need further testing.

In the [obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/), adults without type 2 diabetes lost weight over 48 weeks compared with placebo. The comparison came from placebo: it contained no active drug. That comparison helps show which changes may be due to the drug.

### What it means

This was a result for the people in that study, over that period. It doesn’t predict how much weight an individual would lose. And 48 weeks can’t answer every question about taking a medicine for years.

Retatrutide acts on three hormone signals involved in appetite, blood sugar and energy use. That gives researchers a reason to study it. Counting hormone targets, though, doesn’t tell you which medicine works best. That takes a direct comparison.

## The diabetes trial had a different job

Event · 26 June 2023

ADA announcement · 26 June 2023

### What happened

The [separate diabetes trial](https://pubmed.ncbi.nlm.nih.gov/37385280/) studied adults with type 2 diabetes and found improvements in blood sugar and body weight. Its comparison groups received placebo or another medicine. Unlike the obesity trial, everyone enrolled had type 2 diabetes.

### What it means

The results can’t be rolled into one prediction for everyone who might take retatrutide. Blood sugar and weight are different measures, too. A useful headline keeps the finding attached to the people studied, rather than borrowing the strongest number from each trial.

## Side effects are part of the result

The obesity trial reported stomach and bowel side effects, including nausea, and increases in heart rate. Those findings belong beside the weight loss. A strong result on the scales doesn’t settle the safety question.

These are June 2023 phase 2 findings. They offer early evidence, rather than final answers about long-term benefits and harms. The study’s date helps you place it in the research timeline.

Retatrutide remains an unapproved investigational drug. [FDA’s safety warning](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) says federal law does not allow compounding with it. That is the position in the FDA record reviewed for this report in October 2026. Questions about approved alternatives belong with a licensed U.S. clinician who can prescribe.

## On this page

- [What the two studies found](/research#trial-announcement)

- [The diabetes trial had a different job](/research#diabetes-trial)

- [Side effects are part of the result](/research#trial-safety)

Source review 27 October 2026

[Open the source desk](/references) [Follow the event dates](/#event-index)

Peptide Therapy News is a guide for reading the record, not a clinic, pharmacy or seller.

© 2026 Peptide Therapy News

[References](/references) [About](/about) [Contact](/contact) [Event index](/#event-index)